Company Filing History:
Years Active: 2020-2021
Title: Maurits Kleijnen: Innovator in Immunotherapy
Introduction
Maurits Kleijnen is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on peptides and their applications in treating diseases such as cancer. With a total of 2 patents, his research has the potential to impact therapeutic strategies in the medical field.
Latest Patents
Kleijnen's latest patents include groundbreaking inventions related to peptides derived from the Transient receptor potential cation channel subfamily M member 1 (TRPM1). This invention focuses on novel peptides and their complexes bound to recombinant MHC molecules. The technology aims to develop immunotherapeutic reagents that can effectively treat diseases like cancer. Another significant patent involves peptides derived from Lengsin (LGSN), which also emphasizes the creation of complexes with MHC molecules for similar therapeutic applications.
Career Highlights
Throughout his career, Maurits Kleijnen has worked with prominent companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.
Collaborations
Kleijnen has collaborated with notable colleagues such as Alex Powlesland and Meidai Sun. These partnerships have further enhanced his research and development efforts in immunotherapy.
Conclusion
Maurits Kleijnen's innovative work in the field of immunotherapy, particularly through his patents on peptides, showcases his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in cancer treatment and beyond.